Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Glowing dye could reveal invisible cancer clues in the esophagus

NCT ID NCT07643727

Diagnosis Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a fluorescent tracer called WGA-800CW can make precancerous or cancerous cells in Barrett's esophagus glow during endoscopy. The tracer is sprayed onto the esophagus, and special cameras detect the glow. The goal is to find the best dose and see if this method can spot dysplasia that standard scopes miss. About 49 adults with Barrett's esophagus will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
WGA-800CW (a fluorescent tracer made from wheat germ agglutinin)
What this could lead to
If successful, this imaging technique could help doctors find precancerous spots in Barrett's esophagus that are invisible under standard endoscopy, enabling earlier treatment.
What could go wrong
This is an early pilot study with only 49 participants, so results may not apply to everyone. The tracer is sprayed directly onto the esophagus, and its safety and effectiveness are still being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 49 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with confirmed Barrett's esophagus, esophageal dysplasia, or superficial esophageal ade-nocarcinoma. * Patients scheduled for gastroscopy procedure within the UMCG. * Able to provide written informed consent. Exclusion Criteria: * Known allergy to wheat. * Celiac disease. * Dermatitis herpetiformis. * Pregnancy or breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Barrett esophagus adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Barrett adenocarcinoma Barrett esophagus esophageal adenocarcinoma esophagus carcinoma in situ neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Barrett esophagus adenocarcinoma Barrett's esophagus with or without dysplasia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Medical Center Groningen

    Groningen, Provincie Groningen, 9713 GZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.